Autumn Research Update Meeting 2025
Our 2025 Autumn Research Update Meeting will take place once again at the renowned Royal Society of Medicine (RSM), Wimpole Street, London, on Monday 10 November, where guests can look forward to an engaging agenda featuring the latest updates from our funded research. Theme: Revolutionising...
Learn more
Webinar – Sleep and Parkinson’s
Presented by the Journal of Parkinson’s Disease, Cure Parkinson’s and Van Andel Institute. Professor Patrick Brundin is joined by sleep expert Dr Aleksander Videnovic, Professor Michele Hu consultant neurologist at Oxford University Hospitals, Soania Mathur, medical practitioner with Parkinson’s and Professor Jerrah Holth, Washington School…
The Bristol GDNF results
Today – 27th February, 2019 – the long-awaited results of the Phase II GDNF clinical trial were published. GDNF (or glial cell line-derived neurotrophic factor) is a protein that our bodies naturally produce to nurture and support cells. Extensive preclinical research suggested that this protein was particularly supportive of dopamine neurons – a group […]
GDNF trial results published
Results from a pioneering clinical trials programme that delivered an experimental treatment directly into the brain of people with Parkinson’s offer hope that it may be possible to restore damaged neurons. The findings from these ground-breaking trials are published today in Brain and the Journal of Parkinson’s Disease. …
GDNF – The phase 2 Bristol trial
In February 2019, the results of the ground-breaking phase 2 Bristol study investigating the use of a neurotrophic factor called GDNF (Glial cell-derived neurotrophic factor) in people with Parkinson’s were published.
The UP Study – UDCA in Parkinson’s
Today we received word of a new clinical trial for Parkinson’s being initiated here in the UK. This trial – named the UP study – will evaluate the safety and tolerability of a compound called Ursodeoxycholic acid (or UDCA – click here to read the press release). UDCA is clinically available medication that is […]